Before you enter

This is a medical program, not a store

Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:

I'm not ready — exit
Cognitive · Synthetic tuftsin analog (anxiolytic)

Selank

An anxiolytic peptide approved over-the-counter in Russia — with a human evidence base that hasn't been independently replicated in the West.

Selank is a good example of a compound that's a real, approved drug — just not here, and not tested the way US regulators require. Here's the honest breakdown.

At a glance

Drug class
Synthetic peptide analog of tuftsin (an immune-signaling peptide)
FDA status
Not FDA-approved in the US. Regulatory status in flux — verify current Category status before use
Brand names
Approved OTC in Russia and CIS states as an anxiolytic nasal spray
International status
Approved in Russia (since 2009) for generalized anxiety disorder
Route
Intranasal (approved form abroad); subcutaneous injection (common compounded US form)
Prescription
Required if legally compounded in the US

What Selank is

Selank was developed at the Russian Academy of Medical Sciences and is approved over-the-counter in Russia and several CIS countries as an anxiolytic (anti-anxiety) nasal spray. It is not FDA-approved in the US, and most Selank available in the US is sold labeled "for research use only" rather than for human administration.

How it works (proposed)

Selank appears to modulate GABA-A receptor activity, increase brain-derived neurotrophic factor (BDNF) expression, and slow the breakdown of enkephalins (natural opioid-like peptides) — a mechanism distinct from benzodiazepines, without their sedation or dependence profile in the studies conducted so far.

What the evidence shows

The most-cited human study compared roughly 30 Selank patients to 32 patients on medazepam (a benzodiazepine) for generalized anxiety and neurasthenia, reporting anxiolytic effects without sedation. That's real human data — and it's also a small trial, published in a Russian-language journal, using methodology that predates modern Western trial standards, without independent replication outside Russia. Worth taking seriously as a research signal; not equivalent to a Western Phase 3 trial.

Side effects and who it's not for

Reported human use suggests a favorable side-effect profile compared to benzodiazepines — notably without the sedation, dependence, or withdrawal concerns of that drug class. Given the limited independent replication, a full modern safety profile isn't established the way it would be for a Western-approved anxiolytic, which is a reason for provider oversight rather than self-directed use.

The Bioaminex standard for selank

Before starting
Baseline labs + provider review of current regulatory eligibility and evidence limitations
Screening
Mental health history, current psychiatric medications
Dosing
Provider-managed, compounded by a licensed pharmacy only if currently permitted
During therapy
Monitoring for anxiety symptoms and any interaction with other psychiatric medications

The bottom line

Selank has real approval and real human trial data — just from a regulatory and research tradition that hasn't been independently verified in the West. That's a meaningfully different situation than a compound with no human data at all, but it's still not the same as US clinical evidence, and should be framed that way.

Want to know if it's right for you? That's not a question a website can answer — it's a clinical evaluation. Start your intake and a licensed provider will review your goals and your labs.

Start your consultation

Regulatory status as of 2026-07-20.

This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense Selank or any medication.